This HTML5 document contains 173 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://dx.doi.org/10.1002/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34523239
rdf:type
wikibase:Item
schema:description
мақолаи илмӣ наукова стаття, опублікована в травні 2002 vedecký článok wissenschaftlicher Artikel 2002年论文 vědecký článek 2002年論文 articolo scientifico artykuł naukowy vitskapeleg artikkel ২০০২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2002 nî lūn-bûn tudományos cikk 2002年论文 мақолаи илмӣ научна статия 2002年の論文 vitenskapelig artikkel artículu científicu espublizáu en 2002 научни чланак scientific article 2002년 논문 artikulong pang-agham tieteellinen artikkeli บทความทางวิทยาศาสตร์ επιστημονικό άρθρο 2002年论文 articol științific vetenskaplig artikel 2002年论文 2002 թվականի մայիսին հրատարակված գիտական հոդված مقالهٔ علمی wetenschappelijk artikel 2002年論文 artigo científico (publicado na 2002) teaduslik artikkel 2002年论文 artigo científico article scientifique (publié 2002) سائنسی مضمون научни чланак scienca artikolo 2002年論文 מאמר מדעי 2002 թուականի Մայիսին հրատարակուած գիտական յօդուած artículo científico publicado en 2002 სამეცნიერო სტატია artikull shkencor article científic научная статья bài báo khoa học 2002年论文 2002年論文 videnskabelig artikel (udgivet 2002) bilimsel makale مقالة علمية artigo científico (publicado na 2002) mokslinis straipsnis naučni članak article scientific 2002年論文
p:P577
wds:Q34523239-7C675733-AEE4-4B5A-9658-4AE07182A0AC
wdt:P577
2002-05-01T00:00:00Z
p:P407
wds:Q34523239-D1419E00-D107-4062-A631-87E448B2044F
wdt:P407
wd:Q1860
p:P2860
wds:Q34523239-F99BE21C-C750-4D43-AC24-E08F78EDC04D wds:Q34523239-F3ACDD24-D940-46E1-B4D5-9523B4A02258 wds:Q34523239-38659432-32A3-4E95-ADD0-1538F10D67BD wds:Q34523239-3AC31638-943B-4226-B6BC-02530CD84060 wds:Q34523239-16CBF65C-F71C-466F-B773-69F28665E871 wds:Q34523239-27A2C8D7-6F2D-485B-A130-94BA6601A625 wds:Q34523239-C9515506-0623-49CE-8746-8553A5ED213A wds:Q34523239-CCF4C27B-8C24-48EE-ABFB-90B442A1487D wds:Q34523239-CD4D4861-275B-4670-AA27-172B4C2E13B9 wds:Q34523239-D6E70A45-F8FE-4997-B424-18B920340EAD wds:Q34523239-DCB825FD-EDF2-4202-804A-4915EF3E915F wds:Q34523239-D1F7C7EB-E811-44E2-BDC6-002704A042FE wds:Q34523239-D36E1449-CC03-4F1B-A70C-06BDECFAB69C wds:Q34523239-8CE89AE5-A311-493B-9400-4E8AAAA14DB6 wds:Q34523239-79A6A1BE-E210-4BB7-B907-F7D6BBDE044E wds:Q34523239-AA277377-7BB0-4408-BF64-F2494C632E20 wds:Q34523239-AB646F93-1B0B-4BD4-BE94-09385BD39CD7 wds:Q34523239-925DAF1C-4E47-4E4B-8A74-306B68899644 wds:Q34523239-9A32C714-DB07-4839-B03D-A958296C55D7
wdt:P2860
wd:Q70788934 wd:Q74029021 wd:Q28322699 wd:Q34646676 wd:Q73504291 wd:Q70524840 wd:Q77292858 wd:Q51054753 wd:Q64930033 wd:Q70366122 wd:Q33466250 wd:Q72583621 wd:Q67685640 wd:Q34728585 wd:Q34706463 wd:Q34727875 wd:Q49026763 wd:Q49181727 wd:Q42284459
p:P2093
wds:Q34523239-F80FCF8C-E05A-41FA-92B5-99159A3AB558 wds:Q34523239-E4D529AC-7C42-4F87-9AD7-C788CB0DEC98 wds:Q34523239-504C2C28-38D4-4A1D-9767-12FFCA2D504A wds:Q34523239-C2FEDBEE-5635-45CB-83BD-DC7106CABF74 wds:Q34523239-D9C9E126-AC3A-49BC-AC62-7643C128D5B1 wds:Q34523239-159FBA81-F1E4-4F4D-AB0D-411276191E3F wds:Q34523239-0A6033D5-0BC2-4DD4-A859-C44F9E5D4271 wds:Q34523239-3AB7C482-0DE3-4F62-97FF-3D8EAA4C23A5
wdt:P2093
Elizabeth Hung Maria Merino Susan Bakke Ann Rutt Beverly Meadows David Schrump Seth M Steinberg Jame Abraham
rdfs:label
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
skos:prefLabel
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
schema:name
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
p:P50
wds:Q34523239-C4C0BBE6-1894-48A8-87EC-DFF15D9A54E3 wds:Q34523239-E1839199-08F2-4ACA-B455-E4D8ACAE0AE5 wds:Q34523239-307BAC8A-489D-4D2B-A2D5-4F6DCE17F071 wds:Q34523239-41ACC9A7-95DF-4640-9476-20011A761D8F wds:Q34523239-54E7307F-5D18-43F1-A576-12A11F5A20FE wds:Q34523239-7A17B45F-3676-4F1D-931F-B0A245D2D785
wdt:P50
wd:Q89148742 wd:Q90059714 wd:Q88874526 wd:Q97424233 wd:Q58798575 wd:Q123195986
p:P1476
wds:Q34523239-B4BF088C-0B06-4BF7-8759-945C6723DE7D
wdt:P1476
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist
p:P304
wds:Q34523239-A6EB4AA5-83DF-414B-9E1E-172ECDD5CE6C
wdt:P304
2333-2343
p:P31
wds:Q34523239-B30163DF-68FE-4561-AAC5-34DC33B8EA3A
wdt:P31
wd:Q13442814
p:P921
wds:Q34523239-B41810A9-6102-41A3-9766-1EE3B25363EA wds:Q34523239-A3BEF958-1E7E-43AC-9123-DD6C54A50865 wds:Q34523239-AAFDEED8-6F78-443A-AD2A-53E6E78778CC wds:Q34523239-6F075725-6D11-4A0B-876B-5764881A80EB wds:Q34523239-2EAEA273-7F66-431B-899C-53D84F9BF4F8
wdt:P921
wd:Q418817 wd:Q918285 wd:Q18936 wd:Q974135 wd:Q42824440
p:P698
wds:Q34523239-14201E8E-1F03-4FFF-930E-3622C89AD7C0
wdtn:P698
n9:12015757
wdt:P698
12015757
p:P1433
wds:Q34523239-0ED6AB60-0A74-4EF6-B26D-F0A0641FF324
wdt:P1433
wd:Q326041
p:P433
wds:Q34523239-BB956816-C520-4353-B28F-10A8E5873426
p:P478
wds:Q34523239-DDB3628D-1E06-41C6-A9C9-713AEE589438
wdt:P433
9
wdt:P478
94
p:P1104
wds:Q34523239-D103DB9D-ED9A-4D28-896A-2E25D2650E8C
wdt:P1104
11
p:P356
wds:Q34523239-87E2A1B2-8D3E-455E-BCB2-E3FC316CFEF3
wdtn:P356
n12:CNCR.10487
wdt:P356
10.1002/CNCR.10487
p:P5875
wds:Q34523239-FA243332-B4E9-4859-83D9-53C128E4999A
wdt:P5875
11355456